News Briefing channel feed

IPO-bound Intar­cia hauls in $215M, and plans to add more; Pelo­ton rais­es $52M round

9 years ago

Agios sets out to raise $150M; AC Im­mune IPO sets val­u­a­tion at $700M

9 years ago
R&D

Pro­to­cols: RaNA re­cruits Shire vet as new CSO; Catal­ent buys Phar­matek

9 years ago

Pro­to­cols: Till­man Gern­gross's Avi­tide goes back to the well for more ven­ture cash; No­var­tis leads $17M start­up round

9 years ago

Pro­to­cols: No­van down­sizes its IPO; GSK floats idea for gov­ern­ment-backed vac­cine de­vel­op­ment

9 years ago
R&D

Pro­to­cols: Clo­vis surges as FDA rules out a pan­el re­view for ru­ca­parib; suf­fer­ing Tokai will now con­sid­er all op­tions

9 years ago

Pro­to­cols: Retrophin shares soar on promis­ing Phase II da­ta; FDA read­ies Keytru­da re­view for lung can­cer

9 years ago

Pro­to­cols: CoLu­cid shares rock­et up on pos­i­tive mi­graine PhI­II; Sage bags a 'break­through' on post-par­tum de­pres­sion

9 years ago

Pro­to­cols: Hillary Clin­ton takes aim at drug prof­i­teers; Are­na spins out a GPCR biotech in­cu­ba­tor

9 years ago

Pro­to­cols: No­vo chief Sørensen is hand­ing over the reins ear­ly; Cy­to­ki­net­ics moves Am­gen-part­nered heart drug in­to PhI­II

9 years ago

Pro­to­cols: With Nin­laro sales suf­fer­ing, Take­da launch­es huge mul­ti­ple myelo­ma study; Medi­vir split­ting, spin­ning R&D in­to a sep­a­rate com­pa­ny

9 years ago
R&D

Pro­to­cols: CRO in­dus­try poised for steady growth as new work in Chi­na ex­plodes (in a good way); Vec­tura dinged on PhI­II Flu­ti­form flop

9 years ago
R&D

Pro­to­cols: Leap re­verse merges with a fail­ing Macro­cure; Fer­ring bags rights to PhI­II sci­at­i­ca drug

9 years ago

Pro­to­cols: The My­lan furor comes in­to play for Cal­i­for­nia drug ini­tia­tive; Ado­cia con­cedes a PhI­II flop

9 years ago

Pro­to­cols: BeiGene signs up Medi­va­tion’s Amy Pe­ter­son as its new CMO; Ac­ne drug de­vel­op­er files for $60M IPO

9 years ago
Startups
R&D

Pro­to­cols: Cell Med­ica strikes a TCR re­search deal with Uni­ver­si­ty Col­lege Lon­don; UK of­fers ear­ly ac­cess to Ab­b­Vie's vene­to­clax

9 years ago

Pro­to­cols: My­lan’s EpiPen strat­e­gy stirs fresh out­rage over price goug­ing; a flail­ing Wood­ford halts big bonus­es

9 years ago

Pro­to­cols: Ed­i­tas re­cruits a Bris­tol-My­ers vet as CSO; Eli Lil­ly gets a du­bi­ous hon­or for Alzheimer's drug; Voy­ager in the spot­light

9 years ago

Pro­to­cols: Cal­i­co re­cruits a ma­chine learn­ing star for com­pu­ta­tion­al bi­ol­o­gy; On­coMed rais­es $55M

9 years ago

Pro­to­cols: Snubbed at the FDA, again, Chi­as­ma chops staff, again; J&J lands sec­ond BTD for de­pres­sion drug es­ke­t­a­mine

9 years ago

Pro­to­cols: In­fin­i­ty hunts up a buy­er for its dis­ap­point­ing can­cer drug du­velis­ib; Is North­west Bio fi­nal­ly broke?

9 years ago

Pro­to­cols: Valeant sheds as­sets, but falls short on con­sen­sus; What if vot­ers got a chance to weigh in on your tri­al?

9 years ago

Pro­to­cols: Al­ler­gan diss­es gi­ant leaps, con­cen­trates on step­ping stones; As­traZeneca al­so gets a boost from Bris­tol-My­ers’ woes

9 years ago

Pro­to­cols: Did Io­n­is set out to ex­clude side ef­fects? Mer­ck takes an­oth­er step for­ward with Lan­tus biosim­i­lar

9 years ago
First page Previous page 7677787980 Next page Last page
A service from the Financial Times